LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 576

Search options

  1. Book: Utility of blocking aldosterone in the treatment of cardiovascular disease

    Pitt, Bertram

    (European heart journal : Supplements ; 13B)

    2011  

    Author's details ed. by Bertram Pitt
    Series title European heart journal : Supplements ; 13B
    European heart journal
    European heart journal ; Supplements
    Collection European heart journal
    European heart journal ; Supplements
    Language English
    Size B50 S. : Ill., graph. Darst.
    Publisher Oxford Univ. Press
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT016927656
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Book ; Conference proceedings: New insights into the role of aldosterone in cardiorenal disease and the clinical implications

    Pitt, Bertram

    proceedings of a symposium held at the American Heart Association in Anaheim, California, on November 10, 2001

    (American heart journal ; 144,5, Suppl.)

    2002  

    Institution American Heart Association
    Author's details chair: Bertram Pitt
    Series title American heart journal ; 144,5, Suppl.
    Collection
    Language English
    Size 2A, S18 S. : Ill., graph. Darst.
    Publisher Mosby
    Publishing place St. Louis, Mo
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT013512287
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Article ; Online: Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators?

    Pitt, Bertram / Williams, Gordon H

    Circulation

    2024  Volume 149, Issue 6, Page(s) 414–416

    MeSH term(s) Humans ; Aldosterone ; Mineralocorticoid Receptor Antagonists/adverse effects ; Cytochrome P-450 CYP11B2 ; Spironolactone ; Receptors, Mineralocorticoid ; Hypertension
    Chemical Substances Aldosterone (4964P6T9RB) ; Mineralocorticoid Receptor Antagonists ; Cytochrome P-450 CYP11B2 (EC 1.14.15.4) ; Spironolactone (27O7W4T232) ; Receptors, Mineralocorticoid
    Language English
    Publishing date 2024-02-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/CIRCULATIONAHA.123.066314
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Moving Forward by Looking Backwards: The Role of Combination Therapy With a Mineralocorticoid Receptor Antagonist and a Thiazide Diuretic in Patients With Hypertension.

    Pitt, Bertram / Vaidya, Anand

    American journal of hypertension

    2024  Volume 37, Issue 4, Page(s) 261–263

    MeSH term(s) Humans ; Sodium Chloride Symporter Inhibitors/therapeutic use ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Hypertension/drug therapy ; Antihypertensive Agents/therapeutic use ; Diuretics/therapeutic use ; Drug Therapy, Combination ; Aldosterone
    Chemical Substances Sodium Chloride Symporter Inhibitors ; Mineralocorticoid Receptor Antagonists ; Antihypertensive Agents ; Diuretics ; Aldosterone (4964P6T9RB)
    Language English
    Publishing date 2024-01-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 639383-4
    ISSN 1941-7225 ; 1879-1905 ; 0895-7061
    ISSN (online) 1941-7225 ; 1879-1905
    ISSN 0895-7061
    DOI 10.1093/ajh/hpae003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Possible Role of Gut Microbiota Alterations in Myocardial Fibrosis and Burden of Heart Failure in Hypertensive Heart Disease.

    Pitt, Bertram / Diez, Javier

    Hypertension (Dallas, Tex. : 1979)

    2024  

    Abstract: Epidemiological studies have revealed that hypertensive heart disease is a major risk factor for heart failure, and its heart failure burden is growing rapidly. The need to act in the face of this threat requires first an understanding of the ... ...

    Abstract Epidemiological studies have revealed that hypertensive heart disease is a major risk factor for heart failure, and its heart failure burden is growing rapidly. The need to act in the face of this threat requires first an understanding of the multifactorial origin of hypertensive heart disease and second an exploration of new mechanistic pathways involved in myocardial alterations critically involved in cardiac dysfunction and failure (eg, myocardial interstitial fibrosis). Increasing evidence shows that alterations of gut microbiota composition and function (ie, dysbiosis) leading to changes in microbiota-derived metabolites and impairment of the gut barrier and immune functions may be involved in blood pressure elevation and hypertensive organ damage. In this review, we highlight recent advances in the potential contribution of gut microbiota alterations to myocardial interstitial fibrosis in hypertensive heart disease through blood pressure-dependent and blood pressure-independent mechanisms. Achievements in this field should open a new path for more comprehensive treatment of myocardial interstitial fibrosis in hypertensive heart disease and, thus, for the prevention of heart failure.
    Language English
    Publishing date 2024-05-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 423736-5
    ISSN 1524-4563 ; 0194-911X ; 0362-4323
    ISSN (online) 1524-4563
    ISSN 0194-911X ; 0362-4323
    DOI 10.1161/HYPERTENSIONAHA.124.23089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade.

    Pitt, Bertram / Bakris, George L

    European heart journal

    2024  Volume 45, Issue 2, Page(s) 136–138

    MeSH term(s) Humans ; Receptors, Mineralocorticoid ; Hypertension/drug therapy ; Antihypertensive Agents/therapeutic use ; Mineralocorticoid Receptor Antagonists/therapeutic use
    Chemical Substances Receptors, Mineralocorticoid ; Antihypertensive Agents ; Mineralocorticoid Receptor Antagonists
    Language English
    Publishing date 2024-01-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehad299
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book ; Conference proceedings: How can we define heart failure - a new paradigm treatment

    Pitt, Bertram

    proceedings from the 8th International Congress on Cardiovascular Pharmacotherapy and an official satellite symposium, Amsterdam, The Netherlands, 28 March 1999

    (European heart journal : Supplements ; 2A)

    2000  

    Event/congress International Congress on Cardiovascular Pharmacotherapy (8, 1999, Amsterdam)
    Author's details ed. by Bertram Pitt
    Series title European heart journal : Supplements ; 2A
    European heart journal
    European heart journal ; Supplements
    Collection European heart journal
    European heart journal ; Supplements
    Language English
    Size A28 S. : Ill., graph. Darst.
    Publisher Saunders
    Publishing place London u.a.
    Publishing country Great Britain
    Document type Book ; Conference proceedings
    HBZ-ID HT011230309
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  8. Article ; Online: Mark Nicholls speaks to Professor Bertram Pitt and his role as a pioneer in cardiology over the management of heart failure.

    Pitt, Bertram

    European heart journal

    2020  Volume 41, Issue 17, Page(s) 1615–1617

    MeSH term(s) Cardiology ; Heart Failure/therapy ; History, 20th Century ; Humans
    Language English
    Publishing date 2020-05-15
    Publishing country England
    Document type Historical Article ; Journal Article
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehaa149
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Book: Clinical trials in cardiology

    Pitt, Bertram

    (Frontiers in cardiology series)

    1997  

    Author's details ed. by Bertram Pitt
    Series title Frontiers in cardiology series
    Keywords Cardiology ; Clinical Trials
    Language English
    Size VIII, 386 S. : graph. Darst.
    Publisher Saunders
    Publishing place London u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT008009354
    ISBN 0-7020-2156-3 ; 978-0-7020-2156-5
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  10. Article: Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia:

    Rossignol, Patrick / Pitt, Bertram

    Clinical kidney journal

    2023  Volume 16, Issue 8, Page(s) 1221–1225

    Abstract: Old-generation' potassium (K) binders [i.e. sodium (SPS) and calcium polystyrene sulfonate] are widely used, but with substantial heterogeneity across countries to treat hyperkalaemia (HK). However, there are no randomized data to support their chronic ... ...

    Abstract 'Old-generation' potassium (K) binders [i.e. sodium (SPS) and calcium polystyrene sulfonate] are widely used, but with substantial heterogeneity across countries to treat hyperkalaemia (HK). However, there are no randomized data to support their chronic use to manage HK, nor have they been shown to have a renin-angiotensin-aldosterone system inhibitor (RAASi)-enabling effect. These compounds have poor tolerability and an unpredictable onset of action and magnitude of K lowering. Furthermore, SPS may induce fluid overload, owing to the fact that it exchanges K for sodium. Its use has also been associated with colonic necrosis, as emphasized by a black box warning from the US Food and Drug Administration. In contrast, two new K binders, patiromer and sodium zirconium cyclosilicate, have been shown to be safe and well tolerated for chronic management of HK, thereby enabling RAASi optimization, as acknowledged by the latest international cardiorenal guidelines. In view of the lack of reliable evidence regarding the efficacy and safety of the old-generation K binders compared with the placebo-controlled randomized and real-word evidence demonstrating the safety, efficacy and RAASi-enabling effect of the new K binders, clinicians should now use these new K binders to treat HK (
    Language English
    Publishing date 2023-04-21
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2655800-2
    ISSN 2048-8513 ; 2048-8505
    ISSN (online) 2048-8513
    ISSN 2048-8505
    DOI 10.1093/ckj/sfad090
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top